Edwards Lifesciences (EW)
What changed in recent filings
- Institutions — 2 added · 2 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Edwards Lifesciences recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Jul 23, 2026Revenue +13.6% YoY · EPS $0.42Released after the close: Jul 23 close → Jul 24 close, the stock moved -1.4% · over the same window, market +0.1% · sector +0.9%
- 26Q1Released Apr 23, 2026Revenue +16.7% YoY · EPS $0.66Released after the close: Apr 23 close → Apr 24 close, the stock moved +5.6% · over the same window, market +0.8% · sector -0.9%
- 25Q4Released Feb 10, 2026Revenue +13.3% YoY · EPS $0.16Released after the close: Feb 10 close → Feb 11 close, the stock moved +3.0% · over the same window, market +0.0% · sector +0.4%
- 25Q3Released Oct 30, 2025Revenue +14.7% YoY · EPS $0.50Released after the close: Oct 30 close → Oct 31 close, the stock moved -1.2% · over the same window, market +0.3% · sector +0.0%
The next earnings release is estimated around Oct 29, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Edwards Lifesciences
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 6 → 2026 Q2: 6 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Edwards Lifesciences
Institutions we track that reported holding this stock in their most recent 13F.
- Baillie Gifford & Co0.10% of portfolio · held as of 2019 Q1 or earlier
- National Pension Service (Korea)0.06% of portfolio · held as of 2019 Q1 or earlier
- PRIMECAP Management0.18% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associates0.10% of portfolio · since 2020 Q3
- Point72 Asset Management0.18% of portfolio · since 2024 Q4
- Caisse de depot (Quebec)0.12% of portfolio · since 2025 Q1
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves. Its portfolio supports minimally invasive procedures designed for patients with advanced cardiovascular conditions, while its monitoring technologies help clinicians assess heart function and fluid status in surgical and intensive care settings. The company serves hospitals, heart centers, and healthcare professionals across major international markets, with products distributed in the United States, Europe, Japan, and other regions. Headquartered in Irvine, California, and founded in 1958, Edwards Lifesciences is recognized for its role in advancing specialized therapies for complex heart disease.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Edwards Lifesciences is classified under the Biotech & Health sector. See peers below.
Edwards Lifesciences key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Edwards Lifesciences vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
ETFs holding Edwards Lifesciences
Per SEC N-PORT · 2026-06-30 · by weight · factual
EW on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
EW FAQ
What is Edwards Lifesciences (EW)?
Edwards Lifesciences Corporation is a medical technology company focused on structural heart disease and critical care monitoring. Edwards Lifesciences develops and markets transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, and surgical structural heart products used to repair or replace damaged heart valves. Its portfolio supports minimally invasive procedures designed for patients with advanced cardiovascular conditions, while its monitoring technologies help clinicians assess heart function and fluid status in surgical and intensive care settings. The company serves hospitals, heart centers, and healthcare professionals across major international markets, with products distributed in the United States, Europe, Japan, and other regions. Headquartered in Irvine, California, and founded in 1958, Edwards Lifesciences is recognized for its role in advancing specialized therapies for complex heart disease.
What sector is Edwards Lifesciences in?
Edwards Lifesciences is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Edwards Lifesciences's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 14.6%, Operating margin 29.5%, Net margin 15.4%, ROE 10.4%, Debt-to-equity 0.06x. Definitions and interpretation are available on Stocklore.
Where can I analyze Edwards Lifesciences (EW) stock?
On Stocklore you can see EW's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.